Considering Options for Advancing to Injectable Therapy in Patients with Type 2 Diabetes (T2D) Uncontrolled on Oral Antihyperglycemic Medications (OAMs)

Despite increasing awareness and new developments in the treatment and prevention of diabetes, there has been a rapid increase in the number of people with T2D.² Tight glycemic control may reduce the risk of diabetes complications in people with T2D.³ Non-adherence to treatment is a barrier to effective care. Only Read more…

The Efficacy of the GLP-1 Receptor Agonist Drugs, Dulaglutide and Liraglutide, for Control of Hyperglycemia in Type 2 Diabetes (T2D)

Despite increasing awareness and new developments in the treatment and prevention of diabetes, there has been a rapid increase in the number of people with T2D.²Tight glycemic control may reduce the risk of diabetes complications in people with T2D.³ Non-adherence to treatment is a barrier to effective care. Only 50% Read more…

The PARADIGM study

Premixed insulin (75% insulin lispro protamine suspension,  25% insulin lispro) is non-inferior to glargine+lispro. The PARADIGM study  Patients with type 2 diabetes (T2D) can fail to achieve optimal glycaemic control despite  diet, exercise and oral anti-hyperglycaemic agents, however, long-term glycaemic control  on insulin therapy reduces the risk of both micro and Read more…